

Supplementary Table 1: Efficacy based on baseline tumor characteristics.

		2 mg (n = 28)	8 mg (n = 23)	Total (n = 51)
<i>Stage at screening</i>	Metastatic	3/16 (18.8%)	5/14 (35.7%)	8/30 (26.7%)
	Local recurrence	0/2 (0.0%)	0/2 (0.0%)	0/4 (0.0%)
	Both	3/10 (30.0%)	1/7 (14.3%)	4/17 (23.5%)
<i>Primary Tumor Location</i>	Oropharyngeal	2/9 (22.2%)	2/2 (100.0%)	4/11 (36.4%)
	Oral	2/13 (15.4%)	1/13 (7.7%)	3/26 (11.5%)
	Laryngeal	2/3 (66.7%)	2/4 (50.0%)	4/7 (57.1%)
	Nasopharyngeal	-	0/3 (0.0%)	0/3 (0.0%)
	Hypopharyngeal	0/2 (0.0%)	-	0/2 (0.0%)
<i>Anatomical location of secondary lesions</i>	Liver	0/2 (0.0%)	0/2 (0.0%)	0/4 (0.0%)
	Other visceral	2/8 (25.0%)	3/7 (42.9%)	5/15 (33.3%)
	Non-visceral	4/17 (23.5%)	3/14 (21.4%)	7/31 (22.6%)
<i>Prior Lines of Therapy, x/n (%)</i>	0	3/9 (33.3%)	1/3 (33.3%)	4/12 (33.3%)
	1	2/15 (13.3%)	2/11 (18.2%)	4/26 (15.4%)
	2	1/3 (33.3%)	2/6 (33.3%)	3/9 (33.3%)
	3+	0/1 (0.0%)	1/3 (33.3%)	1/4 (25.0%)
<i>PD-L1 expression</i>	≥ 20	4/11 (36.4%)	0/4 (0.0%)	4/15 (26.7%)
	≥ 1 to < 20	2/16 (12.5%)	6/19 (31.6%)	8/35 (22.9%)
	< 1	-	-	-
<i>HPV Status</i>	Positive	3/10 (30.0%)	4/6 (66.7%)	7/16 (43.8%)
	Negative	2/11 (18.2%)	0/6 (0.0%)	2/17 (11.8%)
	Unknown	1/7 (14.3%)	2/11 (18.2%)	3/18 (16.7%)
<i>Prior cetuximab exposure</i>	Yes	0/3 (0%)	1/9 (11.1%)	1/12 (8.3%)
	No	6/20 (30.0%)	5/11 (45.5%)	11/31 (35.5%)